Takeda Reaffirms FY2025 Guidance, Core Revenue Of ¥4,530B And Core Operating Profit Broadly Flat At ¥1,140B; Core EPS Of ¥485

-0.42% Pre

Takeda Pharmaceutical Company Limited

TAK

14.33

-0.42%

0.00% Pre

FY2025 Outlook (unchanged from May 2025)

(Billion yen, except percentages and per share amounts)

Item	FY2025 FORECAST	FY2025 MANAGEMENT GUIDANCE Core Change at CER(Non-IFRS)
Revenue	4,530.0	―
Core Revenue (Non-IFRS)	4,530.0	Broadly flat
Operating Profit	475.0	―
Core Operating Profit (Non-IFRS)	1,140.0	Broadly flat
Net Profit	228.0	―
EPS (Yen)	145	―
Core EPS (Yen) (Non-IFRS)	485	Broadly flat
Adjusted Free Cash Flow (Non-IFRS)	750.0-850.0	―
Annual Dividend per Share (Yen)	200	―

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.